CSI (Cardiac Science Inc) sees "best ever" quarter 1, resolves Philips row
This article was originally published in Clinica
Executive Summary
Shares in Cardiac Science Inc (CSI), the Bothell, Washington-based heart diagnostic and therapeutic device developer, rallied to a 52-week high after the company reported a 43% growth in defibrillator sales during the first quarter of 2007. Said to be its "best ever performance yet", the results were boosted by significant increases in both domestic (+59%) and international (+29%) sales of its automated external defibrillator (AED). However, this was offset by a 16% decline in revenue from cardiac monitoring sales, which the company said has been flat for the last three quarters. Total revenue for the quarter was $41.7m, up 7% from the prior year.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.